Therapeutic methods using vadadustat
AssigneeAkebia Therapeutics, Inc.
InventorsSteven Burke, Ajit Chavan, Zeeshan Khawaja
Life of this patent
Estimating the term…
Abstract
This invention provides methods for the treatment of anemia in patients with chronic kidney disease (CKD) using vadadustat (Compound 1). Methods described herein provide alternative dosing regimens for patients having anemia. In addition, methods herein are suitable for patients converting from a previous anemia treatment including erythropoietin stimulating agent (ESA), patients who are on dialysis (e.g., peritoneal dialysis or hemodialysis), or CKD patients having certain hemoglobin (Hb) levels.
Claims21
A method of treating anemia, comprising administering to a patient having anemia a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,
- or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein the dose comprises about 750 mg to about 1800 mg of Compound 1 three times weekly.
A method of treating anemia, comprising administering to a patient having anemia a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,
- or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for at least about 12 to about 260 weeks, wherein the dose comprises about 750 mg-1800 mg of Compound 1 three times weekly.
A method of treating anemia, comprising administering to a patient having anemia a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,
- or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein the dose comprises about 750 mg-1800 mg of Compound 1 three times weekly, wherein the patient was previously treated with an erythropoietin stimulating agent (ESA), and wherein anemia is anemia associated with or secondary to dialysis-dependent chronic kidney disease (DD-CKD).
Dependencies are inferred from the claim text.